Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system

Sunil ABRAHAM, (Department of Animal Behavior and Physiology)
Srinivasa Prasad RANGASWAMY, (Innov4Sight Health and Biomedical Systems Biologics Laboratory)
Amutha CHINNAIAH (Department of Animal Behavior and Physiology)
Turkish Journal of Biology
2 0
Yıl: 2020 Cilt: 44 Sayı: 1 Sayfa Aralığı: 34 - 47 Metin Dili: İngilizce DOI: 10.3906/biy-1908-32 İndeks Tarihi: 30-04-2020

Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system

Öz:
Vascular endothelial growth factor A (VEGF-A) is an important growth factor that plays a major role in angiogenesis. Withdifferent isoforms distributed in various tissues, the shortest isoform of VEGF-A is VEGF121, one of the physiologically functional variantsnext to VEGF165. It is well known that VEGF has a shorter half-life, and the stability of the protein must be considered in therapeuticaspects. Poly-l-lactide (PLA) microparticles can release the encapsulated protein in a sustained release mode. In this study, the VEGF121gene was cloned and expressed in a prokaryotic expression system (Escherichia coli). The recombinant VEGF121 was encapsulatedwith PLA microparticles and studied in vitro and ex ovo for the sustained release mechanism. The PLA-VEGF microparticles andthe recombinant VEGF121 were explored for their bioactivity in human umbilical vein endothelial cells (HUVEC). VEGF released invitro from PLA microparticles on days 1, 20, and 30 showed remarkable biological activity compared to PBS-loaded PLA microparticlessuch as the ability of the cells to proliferate, migrate, and form tubes similar to recombinant VEGF121. Besides, PLA-VEGF microparticlesand the recombinant VEGF121 were also tested for their proangiogenic action in embryonated eggs by chicken chorioallantoic membraneassay (CAM), and the effect was observed in both forms. This study suggests that PLA-loaded VEGF microparticles in a sustainablerelease format can be effectively used in proangiogenic therapy and reduce the adverse effects caused due to multiple dosages.
Anahtar Kelime:

Konular: Biyoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Adair TH, Montani JP (2010). San Rafael, CA, USA: Morgan & Claypool Life Sciences.
  • Anugraha G, Madhumathi J, Jeya Prita PJ, Kaliraj P (2015). Biodegradable poly-l-lactide based microparticles as controlled release delivery system for filarial vaccine candidate antigens. European Journal of Pharmacology 747: 174-180.
  • Baeshen MN, Al-Hejin AM, Bora RS, Ahmed MM, Ramadan HA et al. (2015). Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives. Journal of Microbiology and Biotechnology 25 (7): 953-962.
  • Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP et al. (2009). The role of vascular endothelial growth factor in wound healing. Journal of Surgical Research 153: 347-358.
  • Beckert S, Farrahi F, Aslam RS, Scheuenstuhl H, Konigsrainer A et al. (2006). Lactate stimulates endothelial cell migration. Wound Repair and Regeneration 14: 321-324.
  • Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP (1998). Tissuespecific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Human Pathology 29: 910-914.
  • Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nature Medicine 9: 669-676.
  • Ferrara N, Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 161: 851-858.
  • Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974.
  • Folkman J, Klagsbrun M (1987). Angiogenic factors. Science 235: 442-447.
  • Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ et al. (2010). Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. Journal of Controlled Release 147: 30-37
  • Geng H, Song H, Qi J, Cui D (2011). Sustained release of VEGF from PLGA nanoparticles embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix. Nanoscale Research Letters 6: 312.
  • Han FY, Thurecht KJ, Whittaker AK, Smith MT (2016). Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Frontiers in Pharmacology 7: 185.
  • He Y, Li Z, Chen Z, Yu X, Ji Z et al. (2018). Effects of VEGF-ANG1-PLA nano-sustained release microspheres on proliferation and differentiation of ADSCs. Cell Biology International 42: 1060-1068.
  • Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ et al. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for vascular angiogenesis. Circulation 107: 1359- 1365.
  • Howie DW, Manthey B, Hay S, Vernon-Roberts B (1993). The synovial response to intraarticular injection in rats of polyethylene wear particles. Clinical Orthopaedics and Related Research 352-357.
  • Huang JC, Liu DY, Dawood MY (1998). The expression of vascular endothelial growth factor isoforms in cultured human endometrial stromal cells and its regulation by 17betaoestradiol. Molecular Human Reproduction 4: 603-607.
  • Jia Q, Xu L, Zha Q, Chi X, Li F et al. (2007). High level expression of HLA-A*0203-BSP fusion protein in Escherichia coli and construction of soluble HLA-A*0203 monomer and tetramer loaded with Epstein-Barr virus peptide. Cellular & Molecular Immunology 4: 301-308.
  • Jung YW, Kim JO, Rah H, Kim JH, Kim YR et al. (2016). Genetic variants of vascular endothelial growth factor are associated with recurrent implantation failure in Korean women. Reproductive BioMedicine Online 32: 190-196.
  • Kaur J, Kumar A, Kaur J (2018). Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. International Journal of Biological Macromolecules 106: 803-822.
  • Kazemi-Lomedasht F, Behdani M, Pooshang Bagheri K, Habibi Anbouhi M, Abolhassani M et al. (2014). Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor. Advanced Pharmaceutical Bulletin 4: 323-328.
  • Kim S, Mohamedali KA, Cheung LH, Rosenblum MG (2007). Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli. Journal of Biotechnology 128: 638-647.
  • Lee BK, Yun Y, Park K (2016). PLA micro- and nano-particles. Advanced Drug Delivery Reviews 107: 176-191.
  • Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC et al. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898-901.
  • Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
  • Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H et al. (2002). Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Molecular Therapy 6: 127-133.
  • Mezu-Ndubuisi OJ, Wang Y, Schoephoerster J, Falero-Perez J, Zaitoun IS et al. (2019). Intravitreal Delivery of VEGF-A165-loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity. Current Eye Research 44: 275-286.
  • Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC et al. (1997). Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proceedings of the National Academy of Sciences of the United States of America 94: 7192-7197.
  • Nakatsu MN, Sainson RC, Perez del Pulgar S, Aoto JN, Aitkenhead M et al. (2003). VEGF (121) and VEGF (165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 83 (12): 1873-1885.
  • Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M et al. (2010). Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry 285: 5532-5540.
  • Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D et al. (2006). Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Reviews and Reports 2: 93-102.
  • Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI et al. (2003). Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. Federation of American Societies for Experimental Biology 17: 100-102.
  • Rosano GL, Ceccarelli EA (2014). Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in Microbiology 5: 172
  • Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ et al. (2012). Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomaterialia 8: 511-518
  • Saini V, Verma SK, Sahoo MK, Kohli DV, Murthy PK (2011). Sufficiency of a single administration of filarial antigens adsorbed on polymeric lamellar substrate particles of poly (L-lactide) for immunization. International Journal of Pharmaceutics 420: 101-110
  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS et al. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985
  • Sharkey AM, Day K, McPherson A, Malik S, Licence D et al. (2000). Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. Journal of Clinical Endocrinology and Metabolism 85: 402-409
  • Shibuya M (2011). Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes and Cancer 2: 1097-1105
  • Shibuya M, Claesson-Welsh L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research 312: 549-560
  • Simamora P, Chern W (2006). Poly-L-lactic acid: an overview. Journal of Drugs in Dermatology 5: 436-440
  • Simons M, Annex BH, Laham RJ, Kleiman N, Henry T et al. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105: 788-793
  • Smith SK (2001). Regulation of angiogenesis in the endometrium. Trends in Endocrinology & Metabolism 12: 147-151
  • Taktak-Ben Amar A, Morjen M, Ben Mabrouk H, AbdelmaksoudDammak R, Guerfali M et al. (2017). Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF165 in E. coli. Applied Microbiology and Biotechnology 7: 33
  • Tonks AJ, Cooper RA, Jones KP, Blair S, Parton J, Tonks A (2003). Honey stimulates inflammatory cytokine production from monocytes. Cytokine 21(5): 242-247.
  • Walsh K, Sriprasad S, Hopster D, Codd J, Mulvin D (2002). Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer and Prostatic Diseases 5: 119- 122
  • Wimasis, 2016a. WimCAM: CAM Assay Image Analysis Solution. Release 1.1. Available at: https://www.wimasis.com/en/ products/2/WimCAM
  • Wimasis, 2016b. WimTube: Tube Formation Assay Image Analysis Solution. Release 4.0. Available at: https://www.wimasis.com/ en/products/13/WimTube
  • Xin H, Zhong C, Nudleman E, Ferrara N (2016). Evidence for proangiogenic functions of VEGF-Ax. Cell 167: 275-284.
APA ABRAHAM S, RANGASWAMY S, CHINNAIAH A (2020). Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. , 34 - 47. 10.3906/biy-1908-32
Chicago ABRAHAM Sunil,RANGASWAMY Srinivasa Prasad,CHINNAIAH Amutha Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. (2020): 34 - 47. 10.3906/biy-1908-32
MLA ABRAHAM Sunil,RANGASWAMY Srinivasa Prasad,CHINNAIAH Amutha Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. , 2020, ss.34 - 47. 10.3906/biy-1908-32
AMA ABRAHAM S,RANGASWAMY S,CHINNAIAH A Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. . 2020; 34 - 47. 10.3906/biy-1908-32
Vancouver ABRAHAM S,RANGASWAMY S,CHINNAIAH A Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. . 2020; 34 - 47. 10.3906/biy-1908-32
IEEE ABRAHAM S,RANGASWAMY S,CHINNAIAH A "Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system." , ss.34 - 47, 2020. 10.3906/biy-1908-32
ISNAD ABRAHAM, Sunil vd. "Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system". (2020), 34-47. https://doi.org/10.3906/biy-1908-32
APA ABRAHAM S, RANGASWAMY S, CHINNAIAH A (2020). Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. Turkish Journal of Biology, 44(1), 34 - 47. 10.3906/biy-1908-32
Chicago ABRAHAM Sunil,RANGASWAMY Srinivasa Prasad,CHINNAIAH Amutha Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. Turkish Journal of Biology 44, no.1 (2020): 34 - 47. 10.3906/biy-1908-32
MLA ABRAHAM Sunil,RANGASWAMY Srinivasa Prasad,CHINNAIAH Amutha Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. Turkish Journal of Biology, vol.44, no.1, 2020, ss.34 - 47. 10.3906/biy-1908-32
AMA ABRAHAM S,RANGASWAMY S,CHINNAIAH A Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. Turkish Journal of Biology. 2020; 44(1): 34 - 47. 10.3906/biy-1908-32
Vancouver ABRAHAM S,RANGASWAMY S,CHINNAIAH A Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system. Turkish Journal of Biology. 2020; 44(1): 34 - 47. 10.3906/biy-1908-32
IEEE ABRAHAM S,RANGASWAMY S,CHINNAIAH A "Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system." Turkish Journal of Biology, 44, ss.34 - 47, 2020. 10.3906/biy-1908-32
ISNAD ABRAHAM, Sunil vd. "Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system". Turkish Journal of Biology 44/1 (2020), 34-47. https://doi.org/10.3906/biy-1908-32
Sayfa Oluşturulma Tarihi
23-04-2024 11:28

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları